7 results about "Pyruvate kinase" patented technology

Methods for preparing pyruvate kinase (PK) activators or salts or hydrates thereof are provided herein. Synthetic methods for preparing pyruvate kinase (PK) activators, or salts or hydrates thereof, are provided herein. Such activators may be prepared using compounds having formula (A-1) and / or formula (B-1). Specific PK activators and various intermediates prepared by and / or used by the synthetic methods described herein are also disclosed.

The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder:wherein RA, RB, RC and RD, X, Y1, Y2, Y3, Z1, Z2 and m are as defined herein.

Provided herein are methods of treating sickle cell disease, methods of increasing hemoglobin levels in a subject diagnosed with sickle cell disease, and methods of reducing hemolysis-associated complications in a subject diagnosed with sickle cell disease, together with kits for such treatments, in a subject in need thereof, comprising administering a Gardos channel inhibitor such as 2,2-bis(4-fluorophenyl)-2-phenylacetamide and a pyruvate kinase activator such as N-(4-((4-(Cyclopropylmethyl)-1-piperazinyl)carbonyl)phenyl)-8- quinolinesulfonamide to the subject. Subjects eligible for treatment include subjects as having hemolysis dominant (HD) sickle cell disease on the basis of laboratory markers, clinical history, and / or sequelae.

The present application relates to the technical field of bioengineering, and particularly relates to a recombinant Saccharomyces cerevisiae and a construction method and application thereof, comprising the following steps: step one, using the whole genome of Enterococcus faecalis as a template, a recombinant strain SC1-1 is constructed; step two, using the recombinant strain SC1-1 as a primary strain, L-lactate dehydrogenase CYB2 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC2; step three, using the recombinant strain SC2 as a primary strain, branched-chain-2-oxo acid decarboxylase THI3 gene of Saccharomyces cerevisiae is knocked out to obtain a recombinant strain SC3; step four, using the whole genome of Saccharomyces cerevisiae as a template, a recombinant strain SC4 is constructed. The present application innovatively optimizes the source of L-lactate dehydrogenase L-LDH, knocks out L-lactate dehydrogenase CYB2 and branched-chain-2-oxo acid decarboxylase THI3, overexpresses pyruvate kinase CDC19 and H(+)-ATPase PMA2, and makes the L-lactic acid production of Saccharomyces cerevisiae increase to 33.45 g / L.

The present invention relates to a novel variant of pyruvate kinase 2 and a method of producing L-aromatic amino acids using the same. The pyruvate kinase 2 variant is obtained by substituting one or more amino acids in the amino acid sequence constituting pyruvate kinase 2 to change the activity of the protein, and a recombinant microorganism comprising the variant is capable of efficiently producing L-tryptophan, L-phenylalanine, or L-tyrosine.

This invention provides the use of a reagent for increasing pyruvate kinase expression levels in the preparation of a drug for treating ocular neovascularization in subjects. The drug provides long-acting treatment with a high safety profile.

A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.